Incorporated in 2008, Integris Medtech Ltd is a diversified India-based global medical products and laboratory solutions company. The company develops, manufactures, commercialises, and sells a broad portfolio of medical devices and solutions spanning cardiovascular devices, clinical diagnostics, and scientific laboratory solutions.
Integris Medtech operates manufacturing facilities in India, Germany, and the Netherlands, supplying products to more than 65 international markets across India, Europe, and Southeast Asia. Its customer base includes over 9,500 laboratories and 2,000 hospitals and cathlabs, supported by a portfolio exceeding 22,000 SKUs across more than 200 brands in laboratory and cardiovascular segments.
The company’s business is structured into two core divisions:
- Cardiovascular Devices – encompassing drug-eluting stents, drug-coated balloons, complex coronary intervention products, and vascular access solutions.
- Laboratory Solutions – covering clinical, research, and industrial laboratory equipment, reagents, and consumables, along with services such as instrument installation, maintenance, and calibration through its BioCal™ brand.
Integris Medtech supports laboratories and hospitals across India, Singapore, Thailand, Malaysia, and the Philippines, serving both public and private sectors.
Its European operations focus primarily on cardiovascular products, including proprietary brands like Chrome and Protégé, while its Rest of World presence spans the Middle East, Africa, and Latin America.
As of June 30, 2025, Integris Medtech employed 1,879 personnel, including sales, service, and application specialists, and had supported more than 15,000 patients across 100+ clinical trial sites globally, reinforcing its commitment to clinical evidence and innovation in MedTech solutions.
| Purpose | Amount (₹ Cr) |
|---|---|
| Repayment/ prepayment, in full or in part, of certain outstanding borrowings, interest accrued and prepayment penalties, as applicable, availed by: | ₹510 |
| The wholly-owned Subsidiaries, namely, Translumina Therapeutics Pvt.Ltd. (Translumina Therapeutics), Transhealth Pvt.Ltd. (Transhealth) ) and HaleMed Medical Pvt.Ltd. | ₹94 |
| The step-down Subsidiaries, namely, CPC Diagnostics Pvt.Ltd., Chemopharm Sdn. Bhd., Chemoscience Pte Ltd., Lifeline Diagnostics Supplies Inc., Hausen Bernstein Co. Ltd, Medigene Sdn. Bhd., Research Instruments Sdn Bhd and Research Instruments Pte. Ltd. | ₹416 |
| General Corporate Purposes | — |
| Metric | 30 Jun 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Total Assets | 4,020 | 3,641 | 2,989 |
| Revenue | 509 | 1,960 | 1,582 |
| PAT | 268 | 71 | -5 |
| EBITDA | 79 | 309 | 190 |
| Net Worth | 3,890 | 2,753 | 2,681 |
| Reserves | 2,300 | 1,151 | 1,136 |
| Total Borrowing | 793 | 1,729 | 813 |
| Category | Sub (x) | Offered | Bid For |
|---|---|---|---|
| QIB | — | Not less than 75% of the Offer | — |
| NII / HNI | — | Not more than 15% of the Offer | — |
| Retail (RII) | — | Not more than 10% of the Offer | — |
* Amount calculated at upper price band (₹0) · ** Total includes all investor categories
- 1 Initiation of Refund 03 Dec 2026
- 2 Credit of Shares to Demat 03 Dec 2026
- Pre-issue EPS of ₹7.
This IPO has relatively lower interest or stretched valuation. Proceed with thorough research and caution.
The information on mainboardgmp.com is provided for educational and informational purposes only.
We are not a Securities and Exchange Board of India (SEBI)-registered investment advisor, analyst, broker, or financial planner. The content, data, and insights on this website, including Grey Market Premium (GMP), subscription data, IPO dates, and market information, are not intended as financial advice or recommendations to buy, sell, or hold securities.
GMP and related IPO data are collected from unofficial market sources and may not reflect actual IPO listing performance or future price movements. You should not rely solely on the information provided here to make financial or investment decisions.
Investing in IPOs and securities involves risk. Always conduct your own research and consult a qualified SEBI-registered financial advisor before making investment decisions. mainboardgmp.com and its owners shall not be liable for any financial losses, trading losses, or damages arising from use of this website.
By accessing and using mainboardgmp.com, you agree to be bound by these Terms & Conditions. If you do not agree with any part of these terms, you should not use this website.
mainboardgmp.com provides information related to IPOs, including Grey Market Premium (GMP), subscription status, IPO dates, company details, and market trends. All content is for informational purposes only.
Nothing on this website constitutes financial, investment, tax, or legal advice. The content does not constitute a recommendation to invest in any securities, and no assurance is made regarding the accuracy, completeness, or reliability of any information. You should independently verify all information and consult qualified professionals before making investment decisions.
We strive to provide accurate and up-to-date information, but we do not guarantee that all content is correct, complete, or current at all times. IPO details and GMP data are subject to change without notice.
All content, design, graphics, and data on this website belong to mainboardgmp.com and may not be copied, reproduced, or redistributed without express written permission.
You agree not to use the website for unlawful purposes or in a way that may harm, disable, or impair the site's operation.
To the maximum extent permitted by law, mainboardgmp.com and its affiliates shall not be liable for any losses, damages, costs, or expenses arising out of your use of this website.
These Terms shall be governed by the laws of India. Any disputes will be subject to the exclusive jurisdiction of courts located in Kolkata, West Bengal.
We reserve the right to modify these Terms at any time. Continued use of the site constitutes acceptance of the updated Terms.
We may collect: email address (if submitted voluntarily), IP address, browser and device information, cookies and usage data. We do not collect sensitive personal information unless voluntarily provided.
Collected data may be used to improve website performance, respond to inquiries, send newsletters or updates (if you subscribe), and analyze traffic through analytics tools.
We use cookies and similar technologies to enhance user experience and track website usage. Users can disable cookies through browser settings.
We may use third-party services (e.g., Google Analytics) that collect demographic and usage data to help us understand traffic and improve services.
We do not sell personal information. We may share data with service providers (e.g., analytics providers) who assist with website operations.
Reasonable measures are taken to protect user data, but no online transmission can be guaranteed 100% secure.
This website is not directed at children under the age of 18.
We may update this Privacy Policy at any time. Continued use of the website constitutes acceptance of changes.
For privacy concerns, please contact us via the Support page.